Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.440
-0.040 (-2.70%)
At close: Jul 26, 2024, 4:00 PM
1.450
+0.010 (0.69%)
After-hours: Jul 26, 2024, 6:40 PM EDT

Akebia Therapeutics Revenue

Akebia Therapeutics had revenue of $32.61M in the quarter ending March 31, 2024, a decrease of -18.49%. This brings the company's revenue in the last twelve months to $187.23M, down -30.88% year-over-year. In the year 2023, Akebia Therapeutics had annual revenue of $194.62M, down -33.46%.

Revenue (ttm)
$187.23M
Revenue Growth
-30.88%
P/S Ratio
1.64
Revenue / Employee
$1,121,108
Employees
167
Market Cap
301.82M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023194.62M-97.86M-33.46%
Dec 31, 2022292.48M80.83M38.19%
Dec 31, 2021211.65M-82.99M-28.17%
Dec 31, 2020294.64M-40.36M-12.05%
Dec 31, 2019335.00M127.26M61.26%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
MultiPlan 959.44M
Accolade 431.53M
AngioDynamics 324.01M
Viemed Healthcare 194.05M
Alimera Sciences 90.22M
SOPHiA GENETICS 64.18M
Aquestive Therapeutics 51.50M
Nyxoah 5.57M
Revenue Rankings